# OnCo record cetuximab-sarotalocan (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/cetuximab-sarotalocan/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "cetuximab-sarotalocan" ;
  schema:name "Cetuximab sarotalocan"@en ;
  schema:description "Cetuximab sarotalocan is an EGFR antibody carrying a light-activated dye: after infusion, a red laser is shone on the tumour and the cells burst. It has been approved in Japan since 2020."@en ;
  schema:url <https://onco.cc/drugs/cetuximab-sarotalocan/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.pharmaceutical-technology.com/data-insights/cetuximab-sarotalocan-rakuten-medical-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/> ;
  onco:status "approved" ;
  onco:modality "Photoimmunotherapy conjugate (anti-EGFR antibody-IR700 dye)" ;
  schema:alternateName "Akalux" ;
  onco:approval "Japan 2020: Unresectable locally advanced or recurrent head and neck cancer (conditional)" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/> ;
  onco:technologies <https://onco.cc/technologies/photoimmunotherapy/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:companies <https://onco.cc/companies/rakuten-medical/> ;
  onco:trials <https://onco.cc/trials/nct06699212/> .